Literature DB >> 19147099

GVHD: a continuing barrier to the safety of allogeneic transplantation.

Pavan Reddy1, Mukta Arora, Martin Guimond, Crystal L Mackall.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19147099      PMCID： PMC2633357          DOI： 10.1016/j.bbmt.2008.10.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  54 in total

Review 1.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

2.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.

Authors:  K M Sullivan; R P Witherspoon; R Storb; H J Deeg; S Dahlberg; J E Sanders; F R Appelbaum; K C Doney; P Weiden; C Anasetti
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

3.  Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse.

Authors:  Katsuaki Sato; Naohide Yamashita; Naomi Yamashita; Masanori Baba; Takami Matsuyama
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

4.  Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients.

Authors:  M Baudard; A Vincent; P Moreau; M F Kergueris; J L Harousseau; N Milpied
Journal:  Bone Marrow Transplant       Date:  2002-09       Impact factor: 5.483

5.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

Authors:  Mohamed L Sorror; Michael B Maris; Barry Storer; Brenda M Sandmaier; Razvan Diaconescu; Christopher Flowers; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2004-04-27       Impact factor: 22.113

6.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Authors:  Sibel Koc; Wendy Leisenring; Mary E D Flowers; Claudio Anasetti; H Joachim Deeg; Richard A Nash; Jean E Sanders; Robert P Witherspoon; Rainer Storb; Frederick R Appelbaum; Paul J Martin
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

7.  Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.

Authors:  Mario Arpinati; Gabriella Chirumbolo; Benedetta Urbini; Francesca Bonifazi; Giuseppe Bandini; Yogen Saunthararajah; Alessandra Zagnoli; Marta Stanzani; Sadia Falcioni; Giulia Perrone; Sante Tura; Michele Baccarani; Damiano Rondelli
Journal:  Biol Blood Marrow Transplant       Date:  2004-02       Impact factor: 5.742

8.  Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation.

Authors:  Francesco F Fagnoni; Barbara Oliviero; Giovanna Giorgiani; Piero De Stefano; Anna Dehò; Carlo Zibera; Nadia Gibelli; Rita Maccario; GianAntonio Da Prada; Marco Zecca; Franco Locatelli
Journal:  Blood       Date:  2004-03-09       Impact factor: 22.113

9.  Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction.

Authors:  Masako Murai; Hiroyuki Yoneyama; Taichi Ezaki; Makoto Suematsu; Yuya Terashima; Akihisa Harada; Hiromasa Hamada; Hitoshi Asakura; Hiromichi Ishikawa; Kouji Matsushima
Journal:  Nat Immunol       Date:  2003-01-13       Impact factor: 25.606

10.  Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers.

Authors:  R Korngold; J Sprent
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307
View more
  13 in total

1.  Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.

Authors:  Craig C Davis; Luciana C Marti; Gregory D Sempowski; Durairaj A Jeyaraj; Paul Szabolcs
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.

Authors:  Everett H Meyer; Andro R Hsu; Joanna Liliental; Andrea Löhr; Mareike Florek; James L Zehnder; Sam Strober; Philip Lavori; David B Miklos; David S Johnson; Robert S Negrin
Journal:  Blood       Date:  2013-05-07       Impact factor: 22.113

Review 3.  Pathogenesis and management of graft-versus-host disease.

Authors:  Sung W Choi; John E Levine; James L M Ferrara
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

4.  Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease.

Authors:  Dongchang Zhao; James S Young; Yu-Hong Chen; Elizabeth Shen; Tangsheng Yi; Ivan Todorov; Peiguo G Chu; Stephen J Forman; Defu Zeng
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

5.  Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice.

Authors:  Jenny Zilberberg; Thea M Friedman; Glenn Dranoff; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-12       Impact factor: 5.742

6.  Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease.

Authors:  Laurent Burnier; François Saller; Linda Kadi; Anne C Brisset; Rocco Sugamele; Lucie Baudino; Françoise Bono; Jean-Marc Herbert; Peter Carmeliet; Marc Schapira; Shozo Izui; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

7.  Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay.

Authors:  M Israeli; T Klein; C Herscovici; R Ram; O Shpilberg; B Sredni; M Yeshurun
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

8.  Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.

Authors:  David H McDermott; Susan E Conway; Tao Wang; Stacy M Ricklefs; Manza A Agovi; Stephen F Porcella; Huong Thi Bich Tran; Edgar Milford; Stephen Spellman; Reza Abdi
Journal:  Blood       Date:  2010-01-12       Impact factor: 22.113

9.  Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts.

Authors:  Omid Shah; John S Tamaresis; Laura Jean Kenyon; Liwen Xu; Pingping Zheng; Puja Gupta; Krish Rangarajan; Stephanie Lee; Stephen Spellman; Sarah Nikiforow; James Zehnder; Everett H Meyer
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-18       Impact factor: 5.742

Review 10.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.